In vitro cancer diagnostics market seen reaching $16.78 billion by 2030

The global in vitro cancer diagnostics market is projected to rise from $11.49 billion in 2025 to $12.36 billion in 2026, with growth expected to continue to $16.78 billion by 2030. Demand is being driven by liquid biopsy adoption, molecular diagnostics, and broader use of AI, sequencing and personalized oncology tools.

Why it matters: - In vitro cancer diagnostics are becoming more central to early cancer detection, monitoring and treatment selection. - The market’s growth signals rising demand for less invasive testing and more precise cancer care. - Liquid biopsy adoption is expanding the reach of cancer testing beyond traditional tissue sampling.

What happened: - The Business Research Company published its In Vitro Cancer Diagnostics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the market will grow from $11.49 billion in 2025 to $12.36 billion in 2026. - The report projects the market will reach $16.78 billion by 2030. - The company also published a free sample of the report and the full market report.

The details: - The market is projected to post a 7.6% CAGR in 2026. - The market is projected to grow at a 7.9% CAGR through 2030. - Historical growth has been driven by rising cancer incidence, wider use of molecular diagnostic techniques, improvements in immunoassay kit development, expansion of diagnostic laboratories and progress in reagent technologies. - Future growth is expected to come from AI-powered predictive analytics, personalized oncology, high-throughput sequencing platforms, point-of-care diagnostics and cloud-based diagnostic software. - Key trends expected during the forecast period include biomarker-led detection methods, genetic profiling tools, multiplex assay advances, integration with laboratory information management systems and rapid diagnostic kits. - In vitro cancer diagnostics use laboratory tests on blood, tissue or other bodily fluids to detect or monitor cancer outside the body. - These diagnostics rely on molecular assays, biomarkers and genetic profiling to identify cancer presence or progression. - Liquid biopsy technologies analyze circulating tumor DNA, circulating tumor cells and exosomes found in fluids such as blood, urine or saliva. - Liquid biopsies can monitor cancer presence, progression and treatment response in real time. - NHS England said in May 2025 that its liquid biopsy blood test rollout is expected to benefit about 15,000 patients with suspected lung cancer and 5,000 women with advanced breast cancer annually. - NHS England said the program is expected to scale from about 2,200 tests in early 2025 to around 20,000 tests per year by 2028. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - Other regions covered in the analysis include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report points to a market shift from traditional cancer testing toward faster, data-driven and less invasive diagnostics. - The emphasis on AI, sequencing and cloud software suggests diagnostics are becoming more connected to broader digital health infrastructure. - The liquid biopsy example from NHS England shows that adoption is moving from research and niche use into broader clinical deployment.

What's next: - The Business Research Company expects growth to continue as personalized oncology and point-of-care testing expand. - Broader adoption of liquid biopsy and biomarker-based testing could deepen demand for diagnostic platforms and software. - The company highlighted additional 2026 report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and updated graphics and tables.

The bottom line: - Cancer diagnostics are shifting toward earlier, less invasive and more data-rich testing, and the market outlook reflects that transition.